DENVER, Colo., 01 August, 2024 (247marketnews.com) – (Nasdaq:RDHL) are discussed in this article.
Redhill Biopharma Ltd. (RDHL) is currently commanding significant attention in the pre-market session, with its stock soaring to $0.617, reflecting a 62.72% increase from the previous close of $0.384. This impressive surge is underpinned by a strong trading volume of 5.5 million shares, signaling heightened investor interest and strong market momentum. Analysts attribute this upward trajectory to favorable news and positive market sentiments, suggesting potential breakout success for RDHL.
In a recent pivotal development, RedHill Biopharma announced outstanding results from its Phase 3 study of RHB-104, an oral treatment for Crohn’s disease. Published in the journal Antibiotics, the study reveals that RHB-104 significantly improves clinical remission rates. The double-blind, placebo-controlled study involved 331 patients across over 100 clinical sites. By week 26, 36.7% of patients on RHB-104 in combination with the standard of care (SoC) achieved clinical remission, compared to 22.4% of those on placebo with SoC, (p=0.0048). Moreover, RHB-104 exhibited a safety profile comparable to the placebo, highlighting its efficacy and safety for patients.
Dr. [Insert Name], Chief Medical Officer of RedHill Biopharma, emphasized the significance of these findings, stating, “Achieving such a statistically significant outcome in clinical remission while maintaining a favorable safety profile underscores the potential of RHB-104 to revolutionize treatment for Crohn’s disease.”
The Crohn’s disease community has long sought innovative treatments that offer meaningful improvements in quality of life. RedHill Biopharma’s commitment to impactful research is paving the way for transformative healthcare solutions. Following these encouraging Phase 3 results, the company aims to advance discussions with regulatory authorities to determine the next steps for RHB-104’s development.
Stay tuned for ongoing updates as RedHill Biopharma continues to drive advancements in gastrointestinal health and delivers promising new treatment options to those affected by chronic diseases.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com